SCHEMBL2788366

SCHEMBL2788366

Cc1cccc2ccc(C(=O)O)c(O)c12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.65
HSD17B10 Q99714 4/20 0.65
KDM4E B2RXH2 3/20 0.65
KMT2A Q03164 3/20 0.65
MEN1 O00255 2/20 0.65
TSHR P16473 1/20 0.65
RXFP1 Q9HBX9 1/20 0.65
HPGD P15428 2/20 0.61
LDHA P00338 1/20 0.53
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
MYC P01106 1/20 0.43
ALB P02768 1/20 0.43
MMP2 P08253 1/20 0.43
SELL P14151 1/20 0.42
SELP P16109 1/20 0.42
WDR5 P61964 1/20 0.42
HNF4A P41235 1/20 0.41
NR4A1 P22736 1/20 0.40
NR4A2 P43354 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8974158 0.86 ALDH1A1 (0.47) ALDH1A1HSD17B10KDM4EKMT2AMEN1
SCHEMBL3389763 0.81 ALDH1A1 (0.69) ALDH1A1HSD17B10KDM4EKMT2AMEN1
SCHEMBL3388726 0.81 HSD17B10 (0.64) ALDH1A1HSD17B10KDM4EKMT2AMEN1
SCHEMBL19203140 0.81 HSD17B10 (0.55) ALDH1A1HSD17B10KDM4EKMT2AMEN1
SCHEMBL5356059 0.80 ALDH1A1 (0.66) ALDH1A1HSD17B10KDM4EKMT2AMEN1
SCHEMBL6917047 0.79 HSD17B10 (0.62) ALDH1A1HSD17B10KDM4EKMT2AMEN1
SCHEMBL6913672 0.79 HSD17B10 (0.62) ALDH1A1HSD17B10KDM4EKMT2AMEN1
SCHEMBL6913528 0.79 HSD17B10 (0.62) ALDH1A1HSD17B10KDM4EKMT2AMEN1
SCHEMBL6912749 0.79 HSD17B10 (0.62) ALDH1A1HSD17B10KDM4EKMT2AMEN1
SCHEMBL6908489 0.79 HSD17B10 (0.62) ALDH1A1HSD17B10KDM4EKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDICK A/S (DK) 2010-02-18 US claimed
CN-101175720-A Novel haloalkyl sulfone substituted compounds useful for the treatment of obesity and diabetes NOVO NORDISK AS (DK) 2008-05-07 CN claimed
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDICK A/S (DK) 2010-02-18 US disclosed
CN-101175720-A Novel haloalkyl sulfone substituted compounds useful for the treatment of obesity and diabetes NOVO NORDISK AS (DK) 2008-05-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES RPS12, GPR119, ATP12A ALDH1A1 899/4885HSD17B10 15/4885KDM4E 2679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.